menu search

Allergy therapeutics posts improved results from hay fever study

Allergy Therapeutics PLC (AIM:AGY) has presented new data showing the use of its grass pollen vaccine can cut hay fever symptoms by around 40%. Poster...

March 1, 2022, 5:20 am

Allergy therapeutics posts improved results from hay fever study

Allergy Therapeutics PLC (AIM:AGY) has presented new data showing the use of its grass pollen vaccine can cut hay fever symptoms by around 40%. Poster...

March 1, 2022, 5:20 am

Context therapeutics prepares for a busy 2022 as it advances women's oncology treatments

If 2021 was a pivotal year for Context Therapeutics (NASDAQ:CNTX) Inc, 2022 promises to be even more so.  Fresh from a US$31.25 million fundraise and...

February 23, 2022, 6:31 am

Context therapeutics prepares for a busy 2022 as it advances women's oncology treatments

If 2021 was a pivotal year for Context Therapeutics (NASDAQ:CNTX) Inc, 2022 promises to be even more so.  Fresh from a US$31.25 million fundraise and...

February 23, 2022, 6:31 am

Context therapeutics prepares for a busy 2022 as it advances women's oncology treatments

If 2021 was a pivotal year for Context Therapeutics (NASDAQ:CNTX) Inc, 2022 promises to be even more so.  Fresh from a US$31.25 million fundraise and...

February 23, 2022, 6:31 am

Biontech, medigene ink immunotherapy pact against cancer

BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapie...

February 22, 2022, 7:31 am

Biontech, medigene ink immunotherapy pact against cancer

BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapie...

February 22, 2022, 7:31 am

Biontech, medigene ink immunotherapy pact against cancer

BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapie...

February 22, 2022, 7:31 am

Alkermes' nemvaleukin shows encouraging anti-tumor activity in pretreated kidney cancer

Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) va...

February 17, 2022, 11:23 am

Alkermes' nemvaleukin shows encouraging anti-tumor activity in pretreated kidney cancer

Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) va...

February 17, 2022, 11:23 am

Alkermes' nemvaleukin shows encouraging anti-tumor activity in pretreated kidney cancer

Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) va...

February 17, 2022, 11:23 am

Hookipa pharma stock surges on hiv pact with gilead

Hookipa Pharma Inc (NASDAQ: HOOK) amended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ: GILD) for arenaviral...

February 16, 2022, 8:17 am

Hookipa pharma stock surges on hiv pact with gilead

Hookipa Pharma Inc (NASDAQ: HOOK) amended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ: GILD) for arenaviral...

February 16, 2022, 8:17 am

Hookipa pharma stock surges on hiv pact with gilead

Hookipa Pharma Inc (NASDAQ: HOOK) amended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ: GILD) for arenaviral...

February 16, 2022, 8:17 am

Fda clears cidara therapeutics' phase 1 trial for immunotherapeutic antiviral for influenza

The FDA has signed off Cidara Therapeutics Inc's (NASDAQ: CDTX) Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC),...

February 14, 2022, 10:12 am

Fda clears cidara therapeutics' phase 1 trial for immunotherapeutic antiviral for influenza

The FDA has signed off Cidara Therapeutics Inc's (NASDAQ: CDTX) Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC),...

February 14, 2022, 10:12 am

Fda clears cidara therapeutics' phase 1 trial for immunotherapeutic antiviral for influenza

The FDA has signed off Cidara Therapeutics Inc's (NASDAQ: CDTX) Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC),...

February 14, 2022, 10:12 am

Week in review: u.s. fda rejects innovent/lilly pd-1 nda based on china-only trial subjects

A US FDA oncology advisory panel rejected the NDA submitted by Innovent and Lilly for their partnered anti-PD-1 antibody, voting 14-1 against approval...

February 13, 2022, 10:35 pm

Week in review: u.s. fda rejects innovent/lilly pd-1 nda based on china-only trial subjects

A US FDA oncology advisory panel rejected the NDA submitted by Innovent and Lilly for their partnered anti-PD-1 antibody, voting 14-1 against approval...

February 13, 2022, 10:35 pm

Week in review: u.s. fda rejects innovent/lilly pd-1 nda based on china-only trial subjects

A US FDA oncology advisory panel rejected the NDA submitted by Innovent and Lilly for their partnered anti-PD-1 antibody, voting 14-1 against approval...

February 13, 2022, 10:35 pm


Search within

Pages Search Results: